RxDoctor Payments Data

Tara Quesnell, DO

Neurology · Carlsbad, CANPI 1619288172

Payments from drug & device makers

$14,247in general payments, 2019–2025

Across 702 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$1K
  • Argenx US, Inc.$655
  • SK Life Science, Inc.$637
  • Biogen$490
  • AstraZeneca$474
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$901%
  • Food & beverage$14,15799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)197$4,223
UCB, Inc.64$1,281
Argenx US, Inc.23$655
SK Life Science, Inc.52$637
Biogen25$490
AstraZeneca(2 entities)20$474
Pfizer32$424
CSL Behring17$401
Jazz Pharmaceuticals Inc.20$396
Lundbeck LLC13$395
Takeda Pharmaceuticals U.S.A., Inc.17$377
Novartis25$360
Lilly USA, LLC17$341
Teva Pharmaceuticals USA, Inc.19$263
Alnylam Pharmaceuticals Inc.8$253
Catalyst Pharmaceuticals, Inc.5$229
Medtronic(3 entities)3$172
Neurocrine Biosciences, Inc.8$160
Harmony Biosciences LLC5$147
Avadel CNS Pharmaceuticals, LLC6$147
Grifols USA, LLC7$129
Biohaven Pharmaceutical Holding Company Ltd.12$122
Amgen(2 entities)5$119
Acadia Pharmaceuticals Inc7$113
Tanabe Pharma America, Inc.5$104
Merz North America, Inc.3$102
Acorda Therapeutics, Inc5$90
MDD US Operations, LLC2$85
Upsher-smith Laboratories LLC5$82
Scilex Pharmaceuticals Inc.5$80
Impel Pharmaceuticals LLC4$72
GRT US Holding, Inc.1$72
Biohaven Pharmaceuticals, Inc.4$72
Janssen Scientific Affairs, LLC2$62
Vertical Pharmaceuticals, LLC3$58
Promius Pharma LLC3$58
Greenwich Biosciences, Inc.2$55
Amneal Pharmaceuticals LLC3$54
Arbor Pharmaceuticals, Inc.4$54
Johnson & Johnson3$52
Neurelis, Inc.3$50
Corium, LLC2$46
Aquestive Therapeutics, Inc.2$44
Abbott2$43
Kyowa Kirin, Inc.2$42
Impel Pharmaceuticals Inc.2$42
Inspire Medical Systems, Inc.1$38
Avanir Pharmaceuticals, Inc.2$36
EMD Serono, Inc.1$33
Xeris Pharmaceuticals, Inc.2$32
Eisai Inc.2$32
Aucta Pharmaceuticals, Inc.3$32
Almatica Pharma LLC2$30
Axsome Therapeutics, Inc.1$27
Hospira, Inc.1$26
Adamas Pharmaceuticals, Inc.1$24
Amylyx Pharmaceuticals, Inc.1$21
Genentech USA, Inc.1$20
Akcea Therapeutics, Inc.1$20
Microtransponder, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,247 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$399,733
Medicare patients
717
Services billed
24,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate29$1,398,453
Gamunex-CImmune Globul G/Gly/Iga Avg 4674$991,463
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5076$678,653
VyvgartEfgartigimod Alfa-Fcab11$595,828
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5031$473,872
RystiggoRozanolixizumab-Noli11$424,717
OctagamImmun Globg(Igg)/Malt/Iga Ov5016$244,408
Emgality PenGalcanezumab-Gnlm32$29,092
Nurtec OdtRimegepant Sulfate20$23,569
UbrelvyUbrogepant12$9,928
Pyridostigmine Bromide59$5,781
Gabapentin148$2,921
Azathioprine13$1,742
Duloxetine Hcl61$1,458
Pregabalin34$1,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$229$1,398,45329 claims
Grifols USA, LLCGamunex-C$129$991,46374 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$377$678,65376 claims
Argenx US, Inc.Vyvgart$655$595,82811 claims
CSL BehringPrivigen$401$473,87231 claims
UCB, Inc.Rystiggo$1,281$424,71711 claims
PfizerOctagam, Nurtec Odt$424$267,97636 claims
AbbVieUbrelvy$4,223$9,92812 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$54$5,78159 claims
Upsher-smith Laboratories LLCTopiramate$82$10513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →